We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Zeynep Eroglu

Zeynep Eroglu MD

Medical Oncologist, Department of Cutaneous Oncology, Moffitt Cancer Center; Assistant Professor, Department of Oncologic Sciences, University of South Florida Morsani College of Medicine, Tampa, Florida
Dr. Eroglu is a medical oncologist in the Department of Cutaneous Oncology at Moffitt Cancer Center and an assistant professor in the Department of Oncologic Sciences at the University of South Florida Morsani College of Medicine. Her clinical focus is on treating patients with advanced melanoma and other skin cancers, including basal cell carcinoma and Merkel cell carcinoma, and participating in clinical trials. Dr. Eroglu’s research interests are translational and clinical research in targeted therapies and combination immunotherapeutics for melanoma and other skin cancers, along with development of personalized treatment strategies and biomarkers for patients with melanoma. 

Recent Contributions to PracticeUpdate:

  1. Combination Immunotherapy for Advanced Uveal Melanoma
  2. Management of Advanced Melanoma After Progression on Anti-PD1 Therapy
  3. Intratumoral Tilsotolimod Plus Ipilimumab for Advanced Melanoma After PD-1 Inhibitor Progression
  4. Adjuvant Nivolumab Versus Ipilimumab for Resected Stage III/IV Melanoma
  5. ESMO 2020: Recommendations From Dr. Zeynep Eroglu for Melanoma
  6. Toxicity in Combination Immune Checkpoint Inhibitor and Radiation Therapy
  7. Atezolizumab, Vemurafenib, and Cobimetinib as First-Line Treatment for Unresectable Advanced BRAFV600 Mutation–Positive Melanoma
  8. Adjuvant Nivolumab Plus Ipilimumab or Nivolumab Monotherapy vs Placebo in Patients With Resected Stage IV Melanoma With No Evidence of Disease
  9. The EORTC-DeCOG Nomogram Adequately Predicts Outcomes of Patients With SLN+ Melanoma
  10. Management of Early Melanoma Recurrence Despite Adjuvant Anti–PD-1 Antibody Therapy

Most Read This Week

Recently Updated